HomeInsights52 Week High Stocks

Orchid Pharma Ltd 52 Week High

Orchid Pharma Ltd 52 Week High

stocks purchased

₹ 1.1 Cr

Volume transacted

stocks purchased

7.9 K

stocks traded

Last Updated time: 05 Nov 14:09 PM

Image

Orchid Pharma Ltd

NSE: ORCHPHARMA

YEARHIGH

1591.55

Last updated on: Nov 04, 2024

Key Highlights

  • The 52 Week HIGH of Orchid Pharma Ltd is ₹ 1591 as of 04 Nov 24.

Company Fundamentals for Orchid Pharma Ltd

No data available

Market price Over Time

1M

1Y

3Y

5Y

Monitoring Orchid Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPriceleft
04 Nov 20241394.75
01 Nov 20241449.3
31 Oct 20241456.2
30 Oct 20241390.7
29 Oct 20241309.25
28 Oct 20241283.3
25 Oct 20241255.45
24 Oct 20241325.25
23 Oct 20241280.85
22 Oct 20241237.9

Asset Value vs Market Value of Orchid Pharma Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Historical Revenue of Orchid Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Orchid Pharma Ltd

No data available

* All values are in crore

Orchid Pharma Ltd News Hub

News

Orchid Pharma announces board meeting date

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 August 20...

Read more

10 Aug 202412:49

News

Orchid Pharma to conduct AGM

Orchid Pharma announced that the Annual General Meeting (AGM) of the company will be held ...

Read more

18 Jul 202420:35

News

Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam

Cefepime-Enmetazobactam has been approved for the treatment of complicated urinary tract i...

Read more

29 Jun 202410:08

News

Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India

Orchid Pharma announced the launch of its new drug - Cefepime-Enmetazobactam, which has be...

Read more

28 Jun 202419:23

News

Orchid Pharma receives DCGI approval for Enmetazobactam

Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manuf...

Read more

06 Jun 202413:06

News

Orchid Pharma gains on DCGI nod for new antibiotic drug combination

DCGI has also granted permission to manufacture and market finished dosage form (FDF) of C...

Read more

06 Jun 202412:38

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for 52 Week High of Orchid Pharma Ltd

What is the significance of Orchid Pharma Ltd reaching its 52-week high?

Orchid Pharma Ltd reaching its 52-week high indicates strong market confidence and a positive outlook on the company's financial health and growth prospects. This milestone often reflects successful business performance and can boost investor sentiment.

Why do investors monitor Orchid Pharma Ltd 52-week high?

Investors monitor Orchid Pharma Ltd 52-week high to gauge the stock's peak performance and overall market strength, which can indicate robust financial health and growth potential. It also helps them assess if the stock is trading near its maximum value, influencing decisions on buying, holding, or selling.

Is Orchid Pharma Ltd a good buy when it hits its 52-week high?

Whether Orchid Pharma Ltd is a good buy at its 52-week high depends on various factors, including the company's future growth prospects, overall market conditions, individual investment strategies, and other important Orchid Pharma Ltd fundamentals.

What should I consider before investing in Orchid Pharma Ltd at its 52-week high?

Before investing in Orchid Pharma Ltd at its 52-week high, consider evaluating the company's recent financial performance, growth potential, and overall market conditions to ensure it aligns with your investment goals. Additionally, assess whether the stock's current valuation justifies the potential for future returns and if it fits your risk tolerance.

Can Orchid Pharma Ltd stock price continue to rise after reaching its 52-week high?

Orchid Pharma Ltd stock price can continue to rise after reaching its 52-week high if it maintains strong fiscal performance and favorable market conditions. However, future growth depends on numerous factors such as company earnings, industry trends, and broader economic conditions.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*